Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Kangfang Biotech
Shanghai, Shanghai Shi, China
- Ownership
- Private
- Employees
- ~1000
- Development stage
- Other
01
Overview
Kangfang Biotech has successfully commercialized several innovative monoclonal and bispecific antibodies. Notably, cardonilizumab (AK104), a PD‑1/CTLA‑4 bispecific antibody, was the world’s first dual immune checkpoint inhibitor approved for recurrent/metastatic cervical cancer. The company also launched iroximab for moderate to severe plaque psoriasis as the first IL‑12/IL‑23 “dual-targeted” monoclonal antibody approved in China. Multiple other assets are advancing through late-stage clinical trials with strong efficacy signals reported in pivotal studies for oncology and autoimmune indications.
- Therapeutic areas
- DermatologyImmunologyMetabolic DisordersOncology
- Modalities
- Monoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugatemRNA-based drugsCell therapy
- Industry
- Biotech
02
Partnerships
Summit Therapeutics – exclusive license agreement for evosimab commercialization rights outside China ($500M upfront payment)China Biopharmaceuticals – joint development/commercialization of penpulimab [AK105]
Beyond the preview
Go deeper on Kangfang Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kangfang Biotech.